Research Summary

I am a medical oncologist with a specific interest in the genomics of cancer. My laboratory uses a variety of techniques to interrogate three basic themes in the biology and clinical behavior of these deadly cancers: (1) intra- patient tumor heterogeneity at the temporal and anatomic levels, (2) inter-patient heterogeneity between different patients, and (3) tumor-microenvironmental interactions. We use a combination of genetically engineered mouse models, cell lines, and clinically derived samples to interrogate multiple genomic outputs with a focus on genomic DNA and mRNA.

Research Funding

  • April 1, 2019 - March 31, 2024 - Optimizing Treatment Approaches to Lung Cancers Harboring MET Exon 14 mutations, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA239604
  • April 1, 2019 - March 31, 2024 - The structural and functional basis of MET exon 14 activation and acquired drug resistance, Co-Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA230263
  • August 1, 2018 - July 31, 2023 - Tailoring Therapy to Pancreatic Cancer Subtypes, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA222862
  • June 11, 2018 - May 31, 2023 - Genomics and Functional Characterization of NF1-mutated Lung Cancer, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA227807

Education

UC Berkeley, BA, 1996 Genetics
UC Los Angeles, MD, 2002, Medicine

Honors & Awards

  • 1999
    Howard Hughes Medical Institute-NIH Research Scholar, Bethesda MD., Howard Hughes Medical Inst./NIH
  • 2001
    Alpha Omega Alpha, UCLA Chapter, AOA, UCLA
  • 2006
    Amgen Scholar, Amgen Foundation
  • 2007
    ASCO Young Investigator Award, American Society of Clinical Oncology
  • 2012
    AACR PanCAN Career Development Award, American Association of Cancer Research
  • 2013
    Clinical Scholar Development Award , Doris Duke Charitable Foundation

Selected Publications

  1. Carrot-Zhang J, Yao X, Devarakonda S, Deshpande A, Damrauer JS, Silva TC, Wong CK, Choi HY, Felau I, Robertson AG, Castro MAA, Bao L, Rheinbay E, Liu EM, Trieu T, Haan D, Yau C, Hinoue T, Liu Y, Shapira O, Kumar K, Mungall KL, Zhang H, Lee JJ, Berger A, Gao GF, Zhitomirsky B, Liang WW, Zhou M, Moorthi S, Berger AH, Collisson EA, Zody MC, Ding L, Cherniack AD, Getz G, Elemento O, Benz CC, Stuart J, Zenklusen JC, Beroukhim R, Chang JC, Campbell JD, Hayes DN, Yang L, Laird PW, Weinstein JN, Kwiatkowski DJ, Tsao MS, Travis WD, Khurana E, Berman BP, Hoadley KA, Robine N, Meyerson M, Govindan R, Imielinski M Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway.  View on PubMed
  2. Amara D, Wisel SA, Braun HJ, Collisson EA, Friedlander T, Worner G, Roll GR, Hirose R, Stock PG Metastatic Donor-derived Malignancies Following Simultaneous Pancreas-kidney Transplant: Three Case Reports and Management Strategies.  View on PubMed
  3. Gonciarz RL, Collisson EA, Renslo AR Ferrous Iron-Dependent Pharmacology.  View on PubMed
  4. Atreya CE, Collisson EA, Park M, Grenert JP, Behr SC, Gonzalez A, Chou J, Maisel S, Friedlander TW, Freise CE, Shoji J, Semrad TJ, Van Ziffle J, Chin-Hong P Molecular Insights in Transmission of Cancer From an Organ Donor to Four Transplant Recipients.  View on PubMed
  5. Jiang H, Torphy RJ, Steiger K, Hongo H, Ritchie AJ, Kriegsmann M, Horst D, Umetsu SE, Joseph NM, McGregor K, Pishvaian MJ, Blais EM, Lu B, Li M, Hollingsworth M, Stashko C, Volmar K, Yeh JJ, Weaver VM, Wang ZJ, Tempero MA, Weichert W, Collisson EA Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix.  View on PubMed
  6. Cao W, Lee H, Wu W, Zaman A, McCorkle S, Yan M, Chen J, Xing Q, Sinnott-Armstrong N, Xu H, Sailani MR, Tang W, Cui Y, Liu J, Guan H, Lv P, Sun X, Sun L, Han P, Lou Y, Chang J, Wang J, Gao Y, Guo J, Schenk G, Shain AH, Biddle FG, Collisson E, Snyder M, Bivona TG Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma.  View on PubMed
  7. Collisson EA Distinctions with a Difference: RNA Subtyping and Clinical Outcome in Pancreatic Cancer.  View on PubMed
  8. Wang ZJ, Zhang TT, An C, Ko AH, Tempero M, Collisson E, Yeh BM Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma.  View on PubMed
  9. Moroz A, Wang YH, Sharib JM, Wei J, Zhao N, Huang Y, Chen Z, Martinko AJ, Zhuo J, Lim SA, Zhang LH, Seo Y, Carlin S, Leung KK, Collisson EA, Kirkwood KS, Wells JA, Evans MJ Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer.  View on PubMed
  10. Glicksberg BS, Burns S, Currie R, Griffin A, Wang ZJ, Haussler D, Goldstein T, Collisson E Blockchain-Authenticated Sharing of Genomic and Clinical Outcomes Data of Patients With Cancer: A Prospective Cohort Study.  View on PubMed
  11. Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.  View on PubMed
  12. Wang MT, Fer N, Galeas J, Collisson EA, Kim SE, Sharib J, McCormick F Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer.  View on PubMed
  13. Shi Y, Gao W, Lytle NK, Huang P, Yuan X, Dann AM, Ridinger-Saison M, DelGiorno KE, Antal CE, Liang G, Atkins AR, Erikson G, Sun H, Meisenhelder J, Terenziani E, Woo G, Fang L, Santisakultarm TP, Manor U, Xu R, Becerra CR, Borazanci E, Von Hoff DD, Grandgenett PM, Hollingsworth MA, Leblanc M, Umetsu SE, Collisson EA, Scadeng M, Lowy AM, Donahue TR, Reya T, Downes M, Evans RM, Wahl GM, Pawson T, Tian R, Hunter T Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.  View on PubMed
  14. Collisson EA, Bailey P, Chang DK, Biankin AV Molecular subtypes of pancreatic cancer.  View on PubMed
  15. Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.  View on PubMed
  16. Collisson EA Bringing Pancreas Cancer into the Lab.  View on PubMed
  17. Cho RJ, Alexandrov LB, den Breems NY, Atanasova VS, Farshchian M, Purdom E, Nguyen TN, Coarfa C, Rajapakshe K, Prisco M, Sahu J, Tassone P, Greenawalt EJ, Collisson EA, Wu W, Yao H, Su X, Guttmann-Gruber C, Hofbauer JP, Hashmi R, Fuentes I, Benz SC, Golovato J, Ehli EA, Davis CM, Davies GE, Covington KR, Murrell DF, Salas-Alanis JC, Palisson F, Bruckner AL, Robinson W, Has C, Bruckner-Tuderman L, Titeux M, Jonkman MF, Rashidghamat E, Lwin SM, Mellerio JE, McGrath JA, Bauer JW, Hovnanian A, Tsai KY, South AP APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.  View on PubMed
  18. Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI.  View on PubMed
  19. Jha P, Yeh BM, Zagoria R, Collisson E, Wang ZJ The Role of MR Imaging in Pancreatic Cancer.  View on PubMed
  20. North JP, Golovato J, Vaske CJ, Sanborn JZ, Nguyen A, Wu W, Goode B, Stevers M, McMullen K, Perez White BE, Collisson EA, Bloomer M, Solomon DA, Benz SC, Cho RJ Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma.  View on PubMed

Go to UCSF Profiles, powered by CTSI